



PRIOR AUTHORIZATION REQUEST FORM
INTERSTITIAL CYSTITIS MEDICATIONS

Elmiron®, RIMSO-50®

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Elmiron® (pentosane polysulfate sodium), RIMSO-50® (dimethyl sulfoxide)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is this request for an expedited review? By checking the “Yes” box to request an expedited review (24 hours), you are certifying that applying the standard review time frame (72 hours) may place the member's life, health, or ability to regain maximum function in serious jeopardy.	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member been clinically diagnosed with interstitial cystitis or bladder pain syndrome?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the member had urinary tract symptoms for more than 6 weeks?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide baseline voiding symptoms and pain levels
4. Does the member have a urinalysis or urine culture that rules out a urinary tract infection (UTI)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Have other identifiable causes been ruled out (e.g. overactive bladder, endometriosis and vulvodynia, and prostatitis)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Is the request made by, or in consultation with, a urologist?	<input type="checkbox"/>	<input type="checkbox"/>	
7. Has the member participated in conservative treatments (e.g. stress management, pain management, and self-care/behavioral modification)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Has the member had a trial and failure of, or intolerance/contraindication to, amitriptyline and/or cimetidine?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

RIMSO-50			
1. Is the request for RIMSO-50®?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has heparin or lidocaine been trialed?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
ELMIRON			
1. Is the request for Elmiron®?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member had a trial and failure or contraindication/intolerance to at least 2 intravesical agents (e.g. dimethyl sulfoxide, heparin, or lidocaine)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the medication shown efficacy, defined as improvement in baseline voiding symptoms and pain levels?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM- 039
 Origination Date: 09/05/2018
 Reviewed/Revised Date: 03/15/2023
 Next Review Date: 03/15/2024
 Current Effective Date: 04/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.